China Blood Products Industry Report, 2010
  • Nov/2010
  • Hard Copy
  • USD $1,500
  • Pages:59
  • Single User License
    (PDF Unprintable)       
  • USD $1,600
  • Code: YF008
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,400
  • Hard Copy + Single User License
  • USD $1,700
In 2009, Chinese blood products market valued nearly RMB7 billion and it will continue to expand in the next two or three years. The main reasons include:

  • The demand from the downstream of China blood products industry keeps growing.
  • China has a large population, and the aging of which grows obviously severe
  • The indications of blood products are increasing.
Due to the strong demand for albumin in China, the product structure of blood products in China distinguishes from foreign product structure which is dominated by coagulation factor. In 2009, in the product structure of blood products in China, albumin accounted for 68%, intravenous gammaglobulin 21% and coagulation factor 9%.

Product Structure of Blood Products in China, 2009
Source: ResearchInChina

By the end of 2009, 33 Chinese manufacturers of blood products had obtained GMP certification, with the annual plasma volume of around 3,500 tons totally. However, only Hualan Biological Engineering Ltd, Beijing Tiantan Biological Products Co., Ltd, Shanghai RAAS Blood Products Co., Ltd, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, Sino Biopharmaceutical Limited and CNBG Shanghai Institute of Biological Products have the annual plasma volume of over 300 tons respectively.

Hualan Biological Engineering Ltd, as a leading enterprise in China blood products industry, owns a lot of plasma stations and relatively abundant plasma resources with high utilization rate and many varieties. As of October 2010, Hualan Biological Engineering Ltd had had 18 plasma stations, including 13 plasma collection stations in operation, one being examined, 3 under construction and one to be built.

From January to August of 2010, human serum albumin, intravenous human immunoglobulin, tetanus human immunoglobulin, hepatitis B immunoglobulin, human immunoglobulin, human prothrombin complex, rabies immunoglobulin and human clotting Factor VIII of Hualan Biological Engineering Ltd were approved by National Institute for the Control of Pharmaceutical And Biological Products, with the total release volume of 2.272 million bottles.

From January to June of 2010, Hualan Biological Engineering Ltd achieved the revenue of RMB343 million from blood products (a 67% YoY rise), including RMB124 million from human serum albumin (a 13% YoY rise), RMB121 million from intravenous gammaglobulin (a 61% YoY rise) and RMB97.95 million from other products (a 38% YoY rise).

   Gross Margin of Hualan Biological Engineering Ltd (by Product), 2007- H1 2010
Source: ResearchInChina, Hualan Biological Engineering Ltd
1 Profile of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2 Overview of China Blood Products Industry
2.1 General Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policies
2.2.3 Domestic Biopharmaceutical Market
2.3 Plasma Volume
2.4 Import & Export

3 Main Blood Product Markets 
3.1 Human Serum Albumin
3.2 Intravenous Human Immunoglobulin
3.3 Coagulation Factor 
3.4 Hepatitis B Immunoglobulin
3.5 Human Immunoglobulin 
3.6 Human Prothrombin Complex
3.7 Tetanus Immunoglobulin
3.8 Rabies Immunoglobulin

4 Key Manufacturers in China 
4.1  Hualan Biological Engineering Ltd
4.1.1 Profile
4.1.2 Operation
4.1.3 Blood Products
4.2 Shanghai RAAS Blood Products Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Strategies
4.3 Beijing Tiantan Biological Products Co., Ltd 
4.3.1 Profile
4.3.2 Operation
4.3.3 Blood Products
4.4 Sino Biopharmaceutical Limited
4.4.1 Profile
4.4.2 Operation
4.4.3 Shandong Taibang Biological Products Co. Ltd
4.4.4 Xi’an Hui Tian Blood Products Co. Ltd
4.4.5 Guiyang Qianfeng Biological Product Liability Co., Ltd.
4.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
4.5.1 Profile
4.5.2 Operation
4.6 CNBG Shanghai Institute of Biological Products
4.6.1 Profile
4.6.2 Operation
4.7 Shanxi Kangbao Biological Product Co., Ltd
4.7.1 Profile
4.7.2 Operation
4.8 Green Cross
4.8.1 Profile
4.8.2 Operation
4.9 Jiangxi Boya Biopharmaceutical Co., Ltd
4.9.1 Profile
4.9.2 Operation
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Blood Product Industry Chain
Blood Products Market Scale in China, 2003-2009
Product Structure of Blood Products in China, 2009
Product Structure of International Blood Products , 2009
Market Shares of Blood Products Manufacturing Enterprises in China, 2009
Product Lines Contrast of Blood Products Manufacturing Enterprises in China
Release Volume of Blood Products in China, 2007-Aug. 2010
Global Blood Products Market Scale, 2003-2008
Classification of Global Blood Products Manufacturing Enterprises
Sales of Global Blood Products Giants, 2009
Major Policies for Blood Products in China
Sales Revenue and YoY Growth Rate of Biological and Biochemical Pharmacy in China, 2005-2009
Annual Plasma Volume in China, 2002-2009
Production of Blood Products Manufacturing Enterprises in China, 2009
Major Manufacturers and Their Shares in Chinese Human Serum Albumin Market, 2009
Major Manufacturers and Their Shares in Chinese Intravenous Human Immunoglobulin Market, 2009
Per Capita Consumption of Intravenous Human Immunoglobulin in Some Countries and Regions, 2005
Major Manufacturers and Their Shares in Chinese Human Clotting Factor VIII Market, 2009
Major Manufacturers and Their Release Volume & Shares in Chinese Hepatitis B Immunoglobulin Market, 2009
Major Manufacturers and Their Shares in Chinese Human Immunoglobulin Market, 2009
Major Manufacturers and Their Shares in Chinese Human Prothrombin Complex Market, 2009
Major Manufacturers and Their Release Volume in Chinese Tetanus Immunoglobulin Market, 2009
Major Manufacturers and Their Release Volume in Chinese Rabies Immunoglobulin Market, 2009
Operating Income and Net Income of Hualan Biological Engineering Ltd, 2006- H1 2010 
Operating Income of Hualan Biological Engineering Ltd (by Sector), 2007- H1 2010
Operating Income of Hualan Biological Engineering Ltd (by Region), 2007-2009
Gross Margin of Hualan Biological Engineering Ltd (by Product) , 2007- H1 2010
Distribution of Plasma Collection Stations of Hualan Biological Engineering Ltd, by Oct. 2010
Release Volume of Blood Products of Hualan Biological Engineering Ltd, 2007- Aug. 2010
Operating Income of Blood Products of Hualan Biological Engineering Ltd (by Product), 2007- H1 2010
Operating Income and Net Income of Shanghai RAAS Blood Products Co., Ltd, 2006- H1 2010    
Release Volume of Blood Products of Shanghai RAAS Blood Products Co., Ltd, 2007- Aug. 2010     
Operating Income of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005- H1 2010
Gross Margin of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005-2009
Plasma Volume of Shanghai RAAS Blood Products Co., Ltd, 2007-2011E
Operating Income of Shanghai RAAS Blood Products Co., Ltd (by Region), 2008-2009
Operating Income and Net Income of Beijing Tiantan Biological Products Co., Ltd, 2006- Q3 2010   
Operating Income of Beijing Tiantan Biological Products Co., Ltd  (by Product) , 2007-2009
Gross Margin of Beijing Tiantan Biological Products Co., Ltd  (by Product) , 2007-2009
Operating Income of Beijing Tiantan Biological Products Co., Ltd  (by Region), 2007-2009
Operating Income of Blood Products of Beijing Tiantan Biological Products Co., Ltd , 2007- H1 2010 
Operating Income and Gross Profit of Sino Biopharmaceutical Limited, 2007- Q2 2010
Operating Income of Sino Biopharmaceutical Limited (by Product), 2007-2009
Operating Income and Total Profit of Shandong Taibang Biological Products Co. Ltd, 2007-2008
Operating Income and Total Profit of Xi’an Hui Tian Blood Products Co. Ltd, 2007-2008
Operating Income and Total Profit of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2007-2008
Release Volume of Blood Products of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2007-Aug. 2010 
Operating Income and Total Profit of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2007-2008
Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2007-Aug. 2010
Operating Income and Total Profit of CNBG Shanghai Institute of Biological Products, 2007-2008
Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2007-Aug .2010
Operating Income and Total Profit of Shanxi Kangbao Biological Products Co., Ltd, 2007-2008
Release Volume of Blood Products of Shanxi Kangbao Biological Products Co., Ltd, 2007-Aug. 2010
Operating Income and Total Profit of Green Cross (China) , 2007-2008
Release Volume of Blood Products of Green Cross (China), 2007- Aug. 2010
Operating Income and Total Profit of Jiangxi Boya Biopharmaceutical Co., Ltd., 2007-2008
Release Volume of Blood Products of Jiangxi Boya Biopharmaceutical Co., Ltd., 2007- Aug. 2010

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号